Startseite
Kongressberichte 2020
Virtual Edition of the 25th Annual Congress of the European Hematology Association
Oral Sessions
Chronic Lymphoid Neoplasms
Multiple Myeloma
Multiple Myeloma:
New insights in the treatment of newly diagnosed multiple myeloma
Meletios A. Dimopoulos, Ivan Špička, Hang Quach, et al.
The authors of the abstract conclude:
Ixazomib as post-induction maintenance therapy in non-ASCT NDMM pts showed a clinically meaningful 34% reduction in the risk of progression or death, with a well-tolerated safety profile. Ixazomib is the first oral PI maintenance option for non-ASCT NDMM pts.
————————————————————————————————————————————————————————
Saad Usmani, Sikander Ailawadhi, Antje Hoering, et al.
The authors of the abstract conclude:
In the first randomized HRMM study reported to date, the addition of elotuzumab to RVd induction and maintenance did not improve patient outcomes. However, the PFS and OS seen in both arms of the study exceeded the original statistical assumptions and support the role for PI/IMiD combination maintenance therapy for this patient population. The S1211 data will serve as an important benchmark for future HRMM clinical trials.
4:54 ————————————————————————————————————————————————————————
Roberto Mina, Alessandra Larocca, Paolo Corradini, et al.
The authors of the abstract conclude:
Based on the 2-year PFS probability, the primary endpoint of the study was not met. However, Id in a triplet with an alkylating agent or thalidomide was more effective than the doublet Id in elderly NDMM pts, Nevertheless, ITd was burdened by more frequent G3-4 AEs and SAEs resulting in higher treatment discontinuation rates than ICd. Single-agent ixazomib maintenance was well tolerated.
————————————————————————————————————————————————————————
Hartmut Goldschmidt, Elias K. Mai, Hans Salwender, et al.
The authors of the abstract conclude:
The addition of elotuzumab to VRD in newly diagnosed, transplant-eligible MM did not result in increased ≥VGPR rates after four cycles of induction therapy. Whether the addition of elotuzumab yields improved response rates at latter time points (e.g. after consolidation) or a progression-free and/or overall survival benefit needs to be elicited in the final analysis of this trial.
The GMMG-HD6 trial was funded by BMS, Celgene and Chugai.
————————————————————————————————————————————————————————
Katja Weisel, Anne Marie Asemissen, Britta Besemer, et al.
The authors of the abstract conclude:
To the best of our knowledge, we report for the first time on a trial investigating solely HR NDMM. The 4-drug combination of Isa-KRd was administered for the first time for treatment of MM patients. Isa-KRd induction induces deep responses HR MM patients with a high number of MRD negativity. The overall safety profile of Isa-KRd is consistent with previous reports with anti CD38 antibodies combined with SOC regimens. Stem cell mobilization and ASCT is feasible and will be reported seperately. The study is ongoing, with patients continuing to be included.
5:17